ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Gomella on the Impact of the New USPSTF PSA Rating

Leonard G. Gomella, MD
Published: Tuesday, May 22, 2012

Leonard G. Gomella, MD, Bernard W. Godwin Jr. professor of prostate cancer and chairman of the Department of Urology, director of Clinical Affairs, Jefferson Kimmel Cancer Center, discusses the potential implications of the US Preventive Services Task Force (USPSTF) decision to downgrade the rating for prostate-specific antigen (PSA) screening.

Gomella explains that many different opinions exist concerning PSA screening. However, the USPSTF rating holds more authority than other organizations because of its connection to the 2010 Affordable Care Act, which stipulates that services receiving a rating of C or D should not be covered by insurance plans. Only those rated A and B should be covered.

The new USPSTF rating for PSA screening is a D, denoting that it will no longer be covered by many health plans. Gomella explains that this represents a significant obstacle for men seeking to have their prostate cancer screened by PSA.

Leonard G. Gomella, MD, Bernard W. Godwin Jr. professor of prostate cancer and chairman of the Department of Urology, director of Clinical Affairs, Jefferson Kimmel Cancer Center, discusses the potential implications of the US Preventive Services Task Force (USPSTF) decision to downgrade the rating for prostate-specific antigen (PSA) screening.

Gomella explains that many different opinions exist concerning PSA screening. However, the USPSTF rating holds more authority than other organizations because of its connection to the 2010 Affordable Care Act, which stipulates that services receiving a rating of C or D should not be covered by insurance plans. Only those rated A and B should be covered.

The new USPSTF rating for PSA screening is a D, denoting that it will no longer be covered by many health plans. Gomella explains that this represents a significant obstacle for men seeking to have their prostate cancer screened by PSA.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x